<!DOCTYPE html>
<html lang="" xml:lang="">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>What are the current strategies to incentive antibiotic development? |  97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES</title>
  <meta name="description" content="<br />
97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES</p>" />
  <meta name="generator" content="bookdown 0.24 and GitBook 2.6.7" />

  <meta property="og:title" content="What are the current strategies to incentive antibiotic development? |  97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES" />
  <meta property="og:type" content="book" />
  
  
  
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="What are the current strategies to incentive antibiotic development? |  97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES" />
  
  
  

<meta name="author" content="Russell E. Lewis, Associate Professor, Infectious Diseases, Department of Medical and Surgical Sciences" />


<meta name="date" content="2022-11-26" />

  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  
<link rel="prev" href="why-has-antibiotic-discovery-faltered-in-recent-years.html"/>

<script src="assets/header-attrs-2.11/header-attrs.js"></script>
<script src="assets/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/fuse.js@6.4.6/dist/fuse.min.js"></script>
<link href="assets/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="assets/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="assets/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="assets/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="assets/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="assets/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="assets/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />








<link href="assets/anchor-sections-1.0.1/anchor-sections.css" rel="stylesheet" />
<script src="assets/anchor-sections-1.0.1/anchor-sections.js"></script>



<style type="text/css">
/* Used with Pandoc 2.11+ new --citeproc when CSL is used */
div.csl-bib-body { }
div.csl-entry {
  clear: both;
}
.hanging div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}
</style>

</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li class="chapter" data-level="" data-path="the-growing-crises-of-antibiotic-development.html"><a href="the-growing-crises-of-antibiotic-development.html"><i class="fa fa-check"></i>The growing crises of antibiotic development</a></li>
<li class="chapter" data-level="" data-path="why-has-antibiotic-discovery-faltered-in-recent-years.html"><a href="why-has-antibiotic-discovery-faltered-in-recent-years.html"><i class="fa fa-check"></i>Why has antibiotic discovery faltered in recent years?</a>
<ul>
<li class="chapter" data-level="" data-path="why-has-antibiotic-discovery-faltered-in-recent-years.html"><a href="why-has-antibiotic-discovery-faltered-in-recent-years.html#scientific-challenges"><i class="fa fa-check"></i>Scientific challenges</a></li>
<li class="chapter" data-level="" data-path="why-has-antibiotic-discovery-faltered-in-recent-years.html"><a href="why-has-antibiotic-discovery-faltered-in-recent-years.html#antibiotic-regulatory-hurdles"><i class="fa fa-check"></i>Antibiotic regulatory hurdles</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="what-are-the-current-strategies-to-incentive-antibiotic-development.html"><a href="what-are-the-current-strategies-to-incentive-antibiotic-development.html"><i class="fa fa-check"></i>What are the current strategies to incentive antibiotic development?</a>
<ul>
<li class="chapter" data-level="" data-path="what-are-the-current-strategies-to-incentive-antibiotic-development.html"><a href="what-are-the-current-strategies-to-incentive-antibiotic-development.html#economic-strategies"><i class="fa fa-check"></i>Economic strategies?</a></li>
</ul></li>
</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./"><p><img src="images/logo.png" style="width:1in" /><br />
97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES</p></a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="what-are-the-current-strategies-to-incentive-antibiotic-development" class="section level2 unnumbered">
<h2>What are the current strategies to incentive antibiotic development?</h2>
<p>Incentives for antibiotics are categorized as either ‘push’ or ‘pull’. Push incentives occur before regulatory approval by the FDA or European Medicines Agency, and the funding supports many projects, including the many that fail before approval. Pull incentives are paid only after regulatory approval and hence only successful products are supported. Both push and pull incentives are required to address our pressing problems.</p>
<p>Many successful initiatives to establish push funding for antibiotics have been developed over the last decade including:</p>
<ul>
<li><a href="https://www.imi.europa.eu/projects-results/project-factsheets/nd4bb">Innovative Medicines Initiative</a> New Drugs for Bad Bugs (launched in 2012; funds made available €223 million</li>
<li><a href="https://carb-x.org/">CARB-X</a> (launched in 2016; funds made available US$455 million)</li>
<li><a href="https://www.repair-impact-fund.com/">Novo Holdings REPAIR Impact Fund</a> (launched in 2018; funds made available US$165 million).</li>
<li><a href="https://www.gardp.org/">Global Antibiotics Research and Development Partnership</a>. GARDP . Funded by over 60 partners in 20 countries. Seeking 500 million dollars to develop 5 new antibiotics by 2025.</li>
<li><a href="https://www.imi.europa.eu/projects-results/project-factsheets/enable">European Gram Negative AntiBacterial Engine (ENABLE)</a></li>
</ul>
<figure>
<center>
<p><img src="images/pushpull.png" /></p>
</center>
<figcaption>
<p><strong>Figure 3. Pathway from drug discovery to regulatory approval and estimated costs.</strong> ADMET- studies to document drug absorption, distribution, metabolism and elimination, and toxicity in animals. PK/PD pharmacokinetic/ pharmacodynamic relationships- i.e. dose response and toxicity relationships from animals.</p>
</figcaption>
</figure>
<p>However, as the Achaogen story illustrates, pull funding may be the greatest challenge. Pull incentives are being actively discussed in the United States and Europe, building on the release of the DRIVE-AB final report in 2018. One of the strategies that has garnered the most attention is the the “Netflix model”</p>
<figure>
<iframe src="https://www.ft.com/video/adada10f-5747-4976-a3e0-958b0165e0ef" loading="lazy" style="width: 100%; height: 600px; border: 0px none;">
</iframe>
<figcaption>
<p><strong>Figure 4. The “Netlfix Model” of Pull Incentives for</strong></p>
</figcaption>
</figure>
</center>
<figcaption>
<p><strong>Figure 2. Push pull incentives in the drug discover and approval process.</strong></p>
</figcaption>
</figure>
<p>What strategies can be used to ensure global access to future antibiotics?</p>
<p>Netflix model for antibiotics?</p>
<figure>
<iframe src="https://www.ft.com/video/adada10f-5747-4976-a3e0-958b0165e0ef" loading="lazy" style="width: 100%; height: 600px; border: 0px none;">
</iframe>
<figcaption>
<p><strong>Figure 4. Changes in life expectancy over 500 years</strong>. Data source: World Health Bank</p>
</figcaption>
</figure>
<div id="economic-strategies" class="section level3 unnumbered">
<h3>Economic strategies?</h3>
<p>Incentives for antibiotics are categorized as either ‘push’ or ‘pull’. Push incentives occur before regulatory approval by the FDA or European Medicines Agency, and the funding supports many projects, including the many that fail before approval. Pull incentives are paid only after regulatory approval and hence only successful products are supported. Both push and pull incentives are required to address our pressing problems.</p>
<div id="refs" class="references csl-bib-body" line-spacing="2">
<div class="csl-entry">
<div class="csl-left-margin">1. </div><div class="csl-right-inline">Bush, K. &amp; Jacoby, G. A. <a href="https://doi.org/10.1128/AAC.01009-09">Updated <span>Functional Classification</span> of <span><span class="math inline">\(\beta\)</span></span>-<span>Lactamases</span></a>. <em>Antimicrobial Agents and Chemotherapy</em> <strong>54</strong>, 969–976 (2010).</div>
</div>
<div class="csl-entry">
<div class="csl-left-margin">2. </div><div class="csl-right-inline">Livermore, D. M. <em>et al.</em> <a href="https://doi.org/10.1093/jac/dkr262">Discovery research: The scientific challenge of finding new antibiotics</a>. <em>Journal of Antimicrobial Chemotherapy</em> <strong>66</strong>, 1941–1944 (2011).</div>
</div>
<div class="csl-entry">
<div class="csl-left-margin">3. </div><div class="csl-right-inline">Kållberg, C. <em>et al.</em> <a href="https://doi.org/10.1371/journal.pone.0205166">Introduction and geographic availability of new antibiotics approved between 1999 and 2014</a>. <em>PLOS ONE</em> <strong>13</strong>, e0205166 (2018).</div>
</div>
<div class="csl-entry">
<div class="csl-left-margin">4. </div><div class="csl-right-inline">Outterson, K., Orubu, E. S. F., Rex, J., Årdal, C. &amp; Zaman, M. H. Patient <span>Access</span> in 14 <span>High-Income Countries</span> to <span>New Antibacterials Approved</span> by the <span>US Food</span> and <span>Drug Administration</span>, <span>European Medicines Agency</span>, <span>Japanese Pharmaceuticals</span> and <span>Medical Devices Agency</span>, or <span>Health Canada</span>, 2010. <em>Clinical Infectious Diseases</em> ciab612 (2021) doi:<a href="https://doi.org/10.1093/cid/ciab612">10.1093/cid/ciab612</a>.</div>
</div>
<div class="csl-entry">
<div class="csl-left-margin">5. </div><div class="csl-right-inline">Echols, R., Ariyasu, M. &amp; Nagata, T. D. <a href="https://doi.org/10.1093/cid/ciz829">Pathogen-focused <span>Clinical Development</span> to <span>Address Unmet Medical Need</span>: <span>Cefiderocol Targeting Carbapenem Resistance</span></a>. <em>Clinical Infectious Diseases</em> <strong>69</strong>, S559–S564 (2019).</div>
</div>
<div class="csl-entry">
<div class="csl-left-margin">6. </div><div class="csl-right-inline">Wouters, O. J., McKee, M. &amp; Luyten, J. <a href="https://doi.org/10.1001/jama.2020.1166">Estimated <span>Research</span> and <span>Development Investment Needed</span> to <span>Bring</span> a <span>New Medicine</span> to <span>Market</span>, 2009-2018</a>. <em>JAMA</em> <strong>323</strong>, 844–853 (2020).</div>
</div>
<div class="csl-entry">
<div class="csl-left-margin">7. </div><div class="csl-right-inline">Årdal, C. <em>et al.</em> <a href="https://doi.org/10.1038/s41579-019-0293-3">Antibiotic development  economic, regulatory and societal challenges</a>. <em>Nature Reviews Microbiology</em> <strong>18</strong>, 267–274 (2020).</div>
</div>
<div class="csl-entry">
<div class="csl-left-margin">8. </div><div class="csl-right-inline">Mullard, A. <a href="https://doi.org/10.1038/d41573-019-00085-w">Achaogen bankruptcy highlights antibacterial development woes</a>. <em>Nature Reviews. Drug Discovery</em> <strong>18</strong>, 411 (2019).</div>
</div>
</div>
</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="why-has-antibiotic-discovery-faltered-in-recent-years.html" class="navigation navigation-prev navigation-unique" aria-label="Previous page"><i class="fa fa-angle-left"></i></a>

    </div>
  </div>
<script src="assets/gitbook-2.6.7/js/app.min.js"></script>
<script src="assets/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="assets/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="assets/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="assets/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="assets/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="assets/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="assets/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"linkedin": false,
"weibo": false,
"instapaper": false,
"vk": false,
"whatsapp": false,
"all": ["facebook", "twitter", "linkedin", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": null,
"text": null
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": null,
"search": false,
"toc": {
"collapse": "subsection"
},
"toolbar": {
"position": "static"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    var src = "true";
    if (src === "" || src === "true") src = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-MML-AM_CHTML";
    if (location.protocol !== "file:")
      if (/^https?:/.test(src))
        src = src.replace(/^https?:/, '');
    script.src = src;
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
